FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023555639> ?p ?o ?g. }

• W2023555639 endingPage "1386" @default.
• W2023555639 startingPage "1380" @default.
• W2023555639 abstract "The aims of the study were twofold: (1) to evaluate the effect of food on the relative oral bioavailability of topotecan gelatin capsules in patients with solid tumours, and (2) to determine the absolute bioavailability of oral topotecan with reference to the intravenous (i.v.) formulation. The study had a randomized two-period cross-over design. On day 1 of the first treatment course patients were administered 2.3 mg m–2 day–1 of oral topotecan with or without a high-fat breakfast. They crossed over to receive the alternate regimen on day 2. In the second course (3 weeks later) fasted patients received topotecan orally (2.3 mg m–2 day–1) or i.v. (1.5 mg m–3 day). They crossed over to receive the alternate regimen on day 2. On days 3–5 of both treatment courses patients received oral topotecan. Plasma pharmacokinetics were performed on days 1 and 2 of the first and second course using a high-performance liquid chromatographic assay. Eighteen patients were enrolled in the study. The ratio of the area under the curve to infinity during fasted and high-fat treatment was 0.93 ± 0.23 (90% confidence interval (CI) 0.83–1.03). Maximal plasma concentrations of topotecan were similar after ingestion of the capsules with (10.6 ± 4.4 ng ml–1) or without food (9.2 ± 4.1 ng ml–1) (P = 0.130). The time needed to reach maximal plasma levels was significantly prolonged after food intake (median 3.1 h, range 2.8–6.1) compared to fasted conditions (2.0 h, range 1.1–8.1) (P = 0.013). The absolute bioavailability of topotecan averaged 42 ± 13% (90% CI 37– 47%). The apparent terminal half-life was significantly longer after administration of oral topotecan (3.9 ± 1.0 h) than after i.v. administration (2.7 ± 0.4 h) (P < 0.001). Topotecan demonstrates suitable bioavailability for oral treatment. Co-administration of the topotecan gelatin capsules with a high-fat breakfast leads to a small decrease in absorption rate but does not affect the extent of absorption." @default.
• W2023555639 created "2016-06-24" @default.
• W2023555639 creator A5000418012 @default.
• W2023555639 creator A5014102153 @default.
• W2023555639 creator A5028153417 @default.
• W2023555639 creator A5041259777 @default.
• W2023555639 creator A5052811082 @default.
• W2023555639 creator A5060265646 @default.
• W2023555639 creator A5062227574 @default.
• W2023555639 creator A5066580363 @default.
• W2023555639 creator A5074342573 @default.
• W2023555639 date "1999-06-11" @default.
• W2023555639 modified "2023-10-06" @default.
• W2023555639 title "Oral topotecan: bioavailability and effect of food co-administration" @default.
• W2023555639 cites W133816401 @default.
• W2023555639 cites W1823160408 @default.
• W2023555639 cites W1883759477 @default.
• W2023555639 cites W1982182991 @default.
• W2023555639 cites W1997361520 @default.
• W2023555639 cites W2011909208 @default.
• W2023555639 cites W2023095479 @default.
• W2023555639 cites W2045359153 @default.
• W2023555639 cites W2056333272 @default.
• W2023555639 cites W2060325999 @default.
• W2023555639 cites W2063892537 @default.
• W2023555639 cites W2066933615 @default.
• W2023555639 cites W2088610332 @default.
• W2023555639 cites W2092998745 @default.
• W2023555639 cites W2148700329 @default.
• W2023555639 cites W2159921901 @default.
• W2023555639 doi "https://doi.org/10.1038/sj.bjc.6690532" @default.
• W2023555639 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2363072" @default.
• W2023555639 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10424739" @default.
• W2023555639 hasPublicationYear "1999" @default.
• W2023555639 type Work @default.
• W2023555639 sameAs 2023555639 @default.
• W2023555639 citedByCount "62" @default.
• W2023555639 countsByYear W20235556392012 @default.
• W2023555639 countsByYear W20235556392013 @default.
• W2023555639 countsByYear W20235556392015 @default.
• W2023555639 countsByYear W20235556392016 @default.
• W2023555639 countsByYear W20235556392018 @default.
• W2023555639 countsByYear W20235556392019 @default.
• W2023555639 countsByYear W20235556392020 @default.
• W2023555639 countsByYear W20235556392022 @default.
• W2023555639 countsByYear W20235556392023 @default.
• W2023555639 crossrefType "journal-article" @default.
• W2023555639 hasAuthorship W2023555639A5000418012 @default.
• W2023555639 hasAuthorship W2023555639A5014102153 @default.
• W2023555639 hasAuthorship W2023555639A5028153417 @default.
• W2023555639 hasAuthorship W2023555639A5041259777 @default.
• W2023555639 hasAuthorship W2023555639A5052811082 @default.
• W2023555639 hasAuthorship W2023555639A5060265646 @default.
• W2023555639 hasAuthorship W2023555639A5062227574 @default.
• W2023555639 hasAuthorship W2023555639A5066580363 @default.
• W2023555639 hasAuthorship W2023555639A5074342573 @default.
• W2023555639 hasBestOaLocation W20235556391 @default.
• W2023555639 hasConcept C112705442 @default.
• W2023555639 hasConcept C126322002 @default.
• W2023555639 hasConcept C142724271 @default.
• W2023555639 hasConcept C181389837 @default.
• W2023555639 hasConcept C193230392 @default.
• W2023555639 hasConcept C204787440 @default.
• W2023555639 hasConcept C27081682 @default.
• W2023555639 hasConcept C2776694085 @default.
• W2023555639 hasConcept C2777056448 @default.
• W2023555639 hasConcept C2781209748 @default.
• W2023555639 hasConcept C2781413609 @default.
• W2023555639 hasConcept C42404028 @default.
• W2023555639 hasConcept C44249647 @default.
• W2023555639 hasConcept C71924100 @default.
• W2023555639 hasConcept C87813604 @default.
• W2023555639 hasConcept C90924648 @default.
• W2023555639 hasConcept C98274493 @default.
• W2023555639 hasConceptScore W2023555639C112705442 @default.
• W2023555639 hasConceptScore W2023555639C126322002 @default.
• W2023555639 hasConceptScore W2023555639C142724271 @default.
• W2023555639 hasConceptScore W2023555639C181389837 @default.
• W2023555639 hasConceptScore W2023555639C193230392 @default.
• W2023555639 hasConceptScore W2023555639C204787440 @default.
• W2023555639 hasConceptScore W2023555639C27081682 @default.
• W2023555639 hasConceptScore W2023555639C2776694085 @default.
• W2023555639 hasConceptScore W2023555639C2777056448 @default.
• W2023555639 hasConceptScore W2023555639C2781209748 @default.
• W2023555639 hasConceptScore W2023555639C2781413609 @default.
• W2023555639 hasConceptScore W2023555639C42404028 @default.
• W2023555639 hasConceptScore W2023555639C44249647 @default.
• W2023555639 hasConceptScore W2023555639C71924100 @default.
• W2023555639 hasConceptScore W2023555639C87813604 @default.
• W2023555639 hasConceptScore W2023555639C90924648 @default.
• W2023555639 hasConceptScore W2023555639C98274493 @default.
• W2023555639 hasIssue "9" @default.
• W2023555639 hasLocation W20235556391 @default.
• W2023555639 hasLocation W20235556392 @default.
• W2023555639 hasLocation W20235556393 @default.
• W2023555639 hasLocation W20235556394 @default.
• W2023555639 hasOpenAccess W2023555639 @default.
• W2023555639 hasPrimaryLocation W20235556391 @default.

• next